Loading
R-5780 is an experimental pill from Rise Therapeutics designed to help immunotherapy drugs work in tumours that resist them. It is in an early trial with PD-1 inhibitors.
R-5780 is an oral immunotherapy developed by Rise Therapeutics to enhance immune checkpoint inhibitor activity in tumours refractory to them or classically unresponsive. It is being tested in a phase 1 trial with PD-1 inhibitors in patients with solid tumours (NCT06398418), sponsored by Rise. No results have been published.
Delivers secreted antigen A (SagA) from Enterococcus faecium to engage microbiome-associated pattern recognition receptors in the gut and potentiate PD-1 and CTLA-4 blockade, as the developer's award abstract describes.
1.R-5780 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"R-5780" OR ABSTRACT:"R-5780" OR TITLE:"R-5780-01" OR ABSTRACT:"R-5780-01") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about R-5780, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/